ID   ALK_HUMAN               Reviewed;        1620 AA.
AC   Q9UM73; Q4ZFX9; Q53QQ6; Q53RZ4; Q59FI3; Q9Y4K6;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   02-NOV-2010, entry version 109.
DE   RecName: Full=ALK tyrosine kinase receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Anaplastic lymphoma kinase;
DE   AltName: CD_antigen=CD246;
DE   Flags: Precursor;
GN   Name=ALK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   GLYCOSYLATION, AND VARIANT VAL-1461.
RX   MEDLINE=97316779; PubMed=9174053; DOI=10.1038/sj.onc.1201062;
RA   Morris S.W., Naeve C.W., Mathew P., James P.L., Kirstein M.N., Cui X.,
RA   Witte D.P.;
RT   "ALK, the chromosome 2 gene locus altered by the t(2;5) in non-
RT   Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase
RT   that is highly related to leukocyte tyrosine kinase (LTK).";
RL   Oncogene 14:2175-2188(1997).
RN   [2]
RP   ERRATUM.
RA   Morris S.W., Naeve C.W., Mathew P., James P.L., Kirstein M.N., Cui X.,
RA   Witte D.P.;
RL   Oncogene 15:2883-2883(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-1461; ARG-1491 AND
RP   GLU-1529.
RX   MEDLINE=97178863; PubMed=9053841; DOI=10.1038/sj.onc.1200849;
RA   Iwahara T., Fujimoto J., Wen D., Cupples R., Bucay N., Arakawa T.,
RA   Mori S., Ratzkin B., Yamamoto T.;
RT   "Molecular characterization of ALK, a receptor tyrosine kinase
RT   expressed specifically in the nervous system.";
RL   Oncogene 14:439-449(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-1461;
RP   ARG-1491 AND GLU-1529.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], CHROMOSOMAL TRANSLOCATION WITH
RP   NPM1, AND VARIANT VAL-1461.
RX   MEDLINE=94167588; PubMed=8122112; DOI=10.1126/science.8122112;
RA   Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G.,
RA   Shapiro D.N., Saltman D.L., Look A.T.;
RT   "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in
RT   non-Hodgkin's lymphoma.";
RL   Science 263:1281-1284(1994).
RN   [7]
RP   FUNCTION AS AN ONCOGENE.
RX   PubMed=11387242;
RA   Simonitsch I., Polgar D., Hajek M., Duchek P., Skrzypek B., Fassl S.,
RA   Lamprecht A., Schmidt G., Krupitza G., Cerni C.;
RT   "The cytoplasmic truncated receptor tyrosine kinase ALK homodimer
RT   immortalizes and cooperates with ras in cellular transformation.";
RL   FASEB J. 15:1416-1418(2001).
RN   [8]
RP   CHROMOSOMAL TRANSLOCATION WITH ALO17 AND CARS.
RX   MEDLINE=22105993; PubMed=12112524; DOI=10.1002/gcc.10033;
RA   Cools J., Wlodarska I., Somers R., Mentens N., Pedeutour F., Maes B.,
RA   De Wolf-Peeters C., Pauwels P., Hagemeijer A., Marynen P.;
RT   "Identification of novel fusion partners of ALK, the anaplastic
RT   lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory
RT   myofibroblastic tumor.";
RL   Genes Chromosomes Cancer 34:354-362(2002).
RN   [9]
RP   SUBSTRATE SPECIFICITY.
RX   PubMed=15938644; DOI=10.1021/bi0472954;
RA   Donella-Deana A., Marin O., Cesaro L., Gunby R.H., Ferrarese A.,
RA   Coluccia A.M., Tartari C.J., Mologni L., Scapozza L.,
RA   Gambacorti-Passerini C., Pinna L.A.;
RT   "Unique substrate specificity of anaplastic lymphoma kinase (ALK):
RT   development of phosphoacceptor peptides for the assay of ALK
RT   activity.";
RL   Biochemistry 44:8533-8542(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1078; TYR-1092;
RP   TYR-1096; TYR-1131; TYR-1278; TYR-1282; TYR-1507; TYR-1584 AND
RP   TYR-1604, AND MASS SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH SEC31A.
RX   PubMed=16161041; DOI=10.1002/ijc.21490;
RA   Panagopoulos I., Nilsson T., Domanski H.A., Isaksson M., Lindblom P.,
RA   Mertens F., Mandahl N.;
RT   "Fusion of the SEC31L1 and ALK genes in an inflammatory
RT   myofibroblastic tumor.";
RL   Int. J. Cancer 118:1181-1186(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-211, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix adenocarcinoma;
RX   PubMed=16565220; DOI=10.1073/pnas.0507066103;
RA   Nousiainen M., Sillje H.H.W., Sauer G., Nigg E.A., Koerner R.;
RT   "Phosphoproteome analysis of the human mitotic spindle.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5391-5396(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1078; TYR-1096;
RP   TYR-1278; TYR-1282; TYR-1283; TYR-1359 AND TYR-1507, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [14]
RP   STRUCTURE BY NMR OF 1571-1589.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the complex of the PTB domain of SNT-2 and 19-
RT   residue peptide (aa 1571-1589) of HALK.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-90; LEU-163; GLN-296; ALA-476;
RP   PHE-560; ILE-680; THR-704; SER-877; MET-1012; ASP-1121; THR-1274;
RP   LEU-1328; ASN-1416; LYS-1419; ARG-1429; ARG-1491 AND GLU-1529.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Orphan receptor with a tyrosine-protein kinase activity.
CC       Appears to play an important role in the normal development and
CC       function of the nervous system. Phosphorylates almost exclusively
CC       at the first tyrosine of the Y-x-x-x-Y-Y motif.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Homodimer. When bound to ligand.
CC   -!- INTERACTION:
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-357361, EBI-1265766;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-357361, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-357361, EBI-2264500;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Expressed in brain and CNS. Also expressed in
CC       the small intestine and testis, but not in normal lymphoid cells.
CC   -!- PTM: N-glycosylated.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALK is found in a
CC       form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with
CC       NPM1. The resulting chimeric NPM1-ALK protein homodimerize and the
CC       kinase becomes constitutively activated. The constitutively active
CC       fusion proteins are responsible for 5-10% of non-Hodgkin
CC       lymphomas.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALK is associated
CC       with inflammatory myofibroblastic tumors (IMTs). Translocation
CC       t(2;11)(p23;p15) with CARS; translocation t(2;4)(p23;q21) with
CC       SEC31A.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALK is associated
CC       with anaplastic large-cell lymphoma (ALCL). Translocation
CC       t(2;17)(p23;q25) with ALO17.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily.
CC   -!- SIMILARITY: Contains 1 LDL-receptor class A domain.
CC   -!- SIMILARITY: Contains 2 MAM domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92714.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALK.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ALK";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U62540; AAB71619.1; -; mRNA.
DR   EMBL; U66559; AAC51104.1; -; mRNA.
DR   EMBL; AB209477; BAD92714.1; ALT_INIT; mRNA.
DR   EMBL; AC106870; AAX93126.1; -; Genomic_DNA.
DR   EMBL; AC093756; AAX88892.1; -; Genomic_DNA.
DR   EMBL; AC074096; AAY15027.1; -; Genomic_DNA.
DR   IPI; IPI00395632; -.
DR   RefSeq; NP_004295.2; -.
DR   UniGene; Hs.654469; -.
DR   PDB; 2KUP; NMR; -; B=1571-1589.
DR   PDB; 2KUQ; NMR; -; A=1571-1589.
DR   PDB; 2XB7; X-ray; 2.50 A; A=1094-1407.
DR   PDB; 2XBA; X-ray; 1.95 A; A=1094-1407.
DR   PDB; 2YS5; NMR; -; B=1571-1589.
DR   PDB; 2YT2; NMR; -; A=1571-1589.
DR   PDB; 3L9P; X-ray; 1.80 A; A=1072-1410.
DR   PDB; 3LCS; X-ray; 1.95 A; A=1072-1410.
DR   PDB; 3LCT; X-ray; 2.10 A; A=1072-1410.
DR   PDBsum; 2KUP; -.
DR   PDBsum; 2KUQ; -.
DR   PDBsum; 2XB7; -.
DR   PDBsum; 2XBA; -.
DR   PDBsum; 2YS5; -.
DR   PDBsum; 2YT2; -.
DR   PDBsum; 3L9P; -.
DR   PDBsum; 3LCS; -.
DR   PDBsum; 3LCT; -.
DR   ProteinModelPortal; Q9UM73; -.
DR   SMR; Q9UM73; 478-671, 1107-1384.
DR   DIP; DIP-5954N; -.
DR   IntAct; Q9UM73; 72.
DR   MINT; MINT-1133857; -.
DR   STRING; Q9UM73; -.
DR   PhosphoSite; Q9UM73; -.
DR   PRIDE; Q9UM73; -.
DR   Ensembl; ENST00000389048; ENSP00000373700; ENSG00000171094.
DR   GeneID; 238; -.
DR   KEGG; hsa:238; -.
DR   UCSC; uc002rmy.1; human.
DR   CTD; 238; -.
DR   GeneCards; GC02M029327; -.
DR   H-InvDB; HIX0030037; -.
DR   HGNC; HGNC:427; ALK.
DR   HPA; HPA010694; -.
DR   MIM; 105590; gene.
DR   Orphanet; 98841; Anaplastic large cell lymphoma.
DR   Orphanet; 635; Neuroblastoma.
DR   PharmGKB; PA24719; -.
DR   eggNOG; prNOG14384; -.
DR   HOGENOM; HBG444678; -.
DR   HOVERGEN; HBG018726; -.
DR   InParanoid; Q9UM73; -.
DR   BRENDA; 2.7.10.1; 247.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   NextBio; 948; -.
DR   ArrayExpress; Q9UM73; -.
DR   Bgee; Q9UM73; -.
DR   CleanEx; HS_ALK; -.
DR   Genevestigator; Q9UM73; -.
DR   GermOnline; ENSG00000171094; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kin...; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kin...; IEA:InterPro.
DR   InterPro; IPR008985; ConA-like_lec_gl.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002172; LDLR_classA_rpt.
DR   InterPro; IPR000998; MAM.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR020735; Tyr_prot_kinase_ALK_rcpt.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR002011; Tyr_prot_kinase_rcpt_2_CS.
DR   Gene3D; G3DSA:4.10.400.10; LDL_rcpt_classA_cys-rich; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF246; Tyr_prot_kinase_ALK_rcpt; 1.
DR   Pfam; PF00629; MAM; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49899; ConA_like_lec_gl; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS01209; LDLRA_1; FALSE_NEG.
DR   PROSITE; PS50068; LDLRA_2; FALSE_NEG.
DR   PROSITE; PS00740; MAM_1; FALSE_NEG.
DR   PROSITE; PS50060; MAM_2; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Chromosomal rearrangement;
KW   Complete proteome; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     18       Potential.
FT   CHAIN        19   1620       ALK tyrosine kinase receptor.
FT                                /FTId=PRO_0000016740.
FT   TOPO_DOM     19   1038       Extracellular (Potential).
FT   TRANSMEM   1039   1059       Helical; (Potential).
FT   TOPO_DOM   1060   1620       Cytoplasmic (Potential).
FT   DOMAIN      264    427       MAM 1.
FT   DOMAIN      437    473       LDL-receptor class A.
FT   DOMAIN      478    636       MAM 2.
FT   DOMAIN     1116   1392       Protein kinase.
FT   NP_BIND    1122   1130       ATP (By similarity).
FT   COMPBIAS    816    940       Gly-rich.
FT   ACT_SITE   1249   1249       Proton acceptor (By similarity).
FT   BINDING    1150   1150       ATP (By similarity).
FT   MOD_RES     211    211       Phosphoserine.
FT   MOD_RES    1078   1078       Phosphotyrosine.
FT   MOD_RES    1092   1092       Phosphotyrosine.
FT   MOD_RES    1096   1096       Phosphotyrosine.
FT   MOD_RES    1131   1131       Phosphotyrosine.
FT   MOD_RES    1278   1278       Phosphotyrosine.
FT   MOD_RES    1282   1282       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1283   1283       Phosphotyrosine.
FT   MOD_RES    1359   1359       Phosphotyrosine.
FT   MOD_RES    1507   1507       Phosphotyrosine.
FT   MOD_RES    1584   1584       Phosphotyrosine.
FT   MOD_RES    1604   1604       Phosphotyrosine.
FT   CARBOHYD    169    169       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    244    244       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    285    285       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    324    324       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    411    411       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    424    424       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    445    445       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    563    563       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    571    571       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    709    709       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    808    808       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    863    863       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    864    864       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    886    886       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    986    986       N-linked (GlcNAc...) (Potential).
FT   VARIANT      90     90       S -> L (in dbSNP:rs34617074).
FT                                /FTId=VAR_041477.
FT   VARIANT     163    163       V -> L (in dbSNP:rs55697431).
FT                                /FTId=VAR_041478.
FT   VARIANT     296    296       E -> Q (in dbSNP:rs56077855).
FT                                /FTId=VAR_041479.
FT   VARIANT     476    476       V -> A (in dbSNP:rs35093491).
FT                                /FTId=VAR_041480.
FT   VARIANT     560    560       L -> F (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041481.
FT   VARIANT     680    680       T -> I (in dbSNP:rs35228363).
FT                                /FTId=VAR_041482.
FT   VARIANT     704    704       A -> T (in dbSNP:rs34829159).
FT                                /FTId=VAR_041483.
FT   VARIANT     868    868       L -> Q (in dbSNP:rs55941323).
FT                                /FTId=VAR_061288.
FT   VARIANT     877    877       A -> S (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041484.
FT   VARIANT    1012   1012       T -> M (in dbSNP:rs35073634).
FT                                /FTId=VAR_041485.
FT   VARIANT    1121   1121       G -> D (in dbSNP:rs55760835).
FT                                /FTId=VAR_041486.
FT   VARIANT    1274   1274       A -> T (in dbSNP:rs45502292).
FT                                /FTId=VAR_041487.
FT   VARIANT    1328   1328       M -> L (in dbSNP:rs56160491).
FT                                /FTId=VAR_041488.
FT   VARIANT    1376   1376       F -> S (in dbSNP:rs17694720).
FT                                /FTId=VAR_055987.
FT   VARIANT    1416   1416       K -> N (in dbSNP:rs55782189).
FT                                /FTId=VAR_041489.
FT   VARIANT    1419   1419       E -> K (in dbSNP:rs56181542).
FT                                /FTId=VAR_041490.
FT   VARIANT    1429   1429       Q -> R (in dbSNP:rs55906201).
FT                                /FTId=VAR_041491.
FT   VARIANT    1461   1461       I -> V (in dbSNP:rs1670283).
FT                                /FTId=VAR_031042.
FT   VARIANT    1491   1491       K -> R (in dbSNP:rs1881420).
FT                                /FTId=VAR_031043.
FT   VARIANT    1529   1529       D -> E (in dbSNP:rs1881421).
FT                                /FTId=VAR_031044.
FT   VARIANT    1599   1599       P -> H (in dbSNP:rs1881423).
FT                                /FTId=VAR_055988.
FT   CONFLICT     36     36       P -> S (in Ref. 1; AAB71619).
SQ   SEQUENCE   1620 AA;  176442 MW;  0733D6C4FD212F41 CRC64;
     MGAIGLLWLL PLLLSTAAVG SGMGTGQRAG SPAAGPPLQP REPLSYSRLQ RKSLAVDFVV
     PSLFRVYARD LLLPPSSSEL KAGRPEARGS LALDCAPLLR LLGPAPGVSW TAGSPAPAEA
     RTLSRVLKGG SVRKLRRAKQ LVLELGEEAI LEGCVGPPGE AAVGLLQFNL SELFSWWIRQ
     GEGRLRIRLM PEKKASEVGR EGRLSAAIRA SQPRLLFQIF GTGHSSLESP TNMPSPSPDY
     FTWNLTWIMK DSFPFLSHRS RYGLECSFDF PCELEYSPPL HDLRNQSWSW RRIPSEEASQ
     MDLLDGPGAE RSKEMPRGSF LLLNTSADSK HTILSPWMRS SSEHCTLAVS VHRHLQPSGR
     YIAQLLPHNE AAREILLMPT PGKHGWTVLQ GRIGRPDNPF RVALEYISSG NRSLSAVDFF
     ALKNCSEGTS PGSKMALQSS FTCWNGTVLQ LGQACDFHQD CAQGEDESQM CRKLPVGFYC
     NFEDGFCGWT QGTLSPHTPQ WQVRTLKDAR FQDHQDHALL LSTTDVPASE SATVTSATFP
     APIKSSPCEL RMSWLIRGVL RGNVSLVLVE NKTGKEQGRM VWHVAAYEGL SLWQWMVLPL
     LDVSDRFWLQ MVAWWGQGSR AIVAFDNISI SLDCYLTISG EDKILQNTAP KSRNLFERNP
     NKELKPGENS PRQTPIFDPT VHWLFTTCGA SGPHGPTQAQ CNNAYQNSNL SVEVGSEGPL
     KGIQIWKVPA TDTYSISGYG AAGGKGGKNT MMRSHGVSVL GIFNLEKDDM LYILVGQQGE
     DACPSTNQLI QKVCIGENNV IEEEIRVNRS VHEWAGGGGG GGGATYVFKM KDGVPVPLII
     AAGGGGRAYG AKTDTFHPER LENNSSVLGL NGNSGAAGGG GGWNDNTSLL WAGKSLQEGA
     TGGHSCPQAM KKWGWETRGG FGGGGGGCSS GGGGGGYIGG NAASNNDPEM DGEDGVSFIS
     PLGILYTPAL KVMEGHGEVN IKHYLNCSHC EVDECHMDPE SHKVICFCDH GTVLAEDGVS
     CIVSPTPEPH LPLSLILSVV TSALVAALVL AFSGIMIVYR RKHQELQAMQ MELQSPEYKL
     SKLRTSTIMT DYNPNYCFAG KTSSISDLKE VPRKNITLIR GLGHGAFGEV YEGQVSGMPN
     DPSPLQVAVK TLPEVCSEQD ELDFLMEALI ISKFNHQNIV RCIGVSLQSL PRFILLELMA
     GGDLKSFLRE TRPRPSQPSS LAMLDLLHVA RDIACGCQYL EENHFIHRDI AARNCLLTCP
     GPGRVAKIGD FGMARDIYRA SYYRKGGCAM LPVKWMPPEA FMEGIFTSKT DTWSFGVLLW
     EIFSLGYMPY PSKSNQEVLE FVTSGGRMDP PKNCPGPVYR IMTQCWQHQP EDRPNFAIIL
     ERIEYCTQDP DVINTALPIE YGPLVEEEEK VPVRPKDPEG VPPLLVSQQA KREEERSPAA
     PPPLPTTSSG KAAKKPTAAE ISVRVPRGPA VEGGHVNMAF SQSNPPSELH KVHGSRNKPT
     SLWNPTYGSW FTEKPTKKNN PIAKKEPHDR GNLGLEGSCT VPPNVATGRL PGASLLLEPS
     SLTANMKEVP LFRLRHFPCG NVNYGYQQQG LPLEAATAPG AGHYEDTILK SKNSMNQPGP
//
